Navigation Links
Safeway Raises Over $9 Million to Fund Prostate Cancer Research
Date:7/25/2012

PLEASANTON, Calif., July 25, 2012 /PRNewswire/ -- Safeway Inc. (NYSE: SWY) today announced that its month-long Prostate Cancer Awareness Campaign raised over $9 million to help find new treatments and an ultimate cure for prostate cancer.

"We are infinitely grateful for all of the customer and community support for a campaign that will help save the lives of countless men worldwide," said Larree Renda, Safeway Executive Vice President and Chair of the Safeway Foundation. "Prostate cancer is the number one cancer killer of men. These contributions, one dollar at a time, are sparing lives by funding critical research and the absolute best treatment at the most renowned cancer centers in North America."

This is the 12th year that Safeway, one of the largest corporate supporters of cancer research, has dedicated the entire month of June to raising funds at its stores, production facilities and corporate offices for prostate cancer research. The company works with the Prostate Cancer Foundation to identify and provide grants for promising research. The outcomes of the nearly 1,600 Safeway-funded research projects include the identification of more than 27 cancer-causing gene fusions, new biomarkers for diagnosis and treatment response assessment and the development of new drugs to deliver more effective treatments for patients with advanced stages of the disease. The death rate has dropped roughly 40 percent in the U.S. alone, meaning nearly 200,000 American men are alive today because of improved treatment.

"The partnership with Safeway, its customers and employees has been nothing short of amazing," said Jonathan Simons, MD, President and CEO of the Prostate Cancer Foundation. "Advancements made possible by these donations are paving the way for better methods to diagnose and treat patients battling the disease."

The 2012 Prostate Cancer Awar
'/>"/>

SOURCE Safeway Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
2. Juventas Therapeutics Raises $22.2 Million Series B Financing
3. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
4. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
5. Cerecor Raises $22 Million Series A Financing
6. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
7. Cowen Healthcare Royalty Partners Raises $1 Billion
8. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
9. Positron Accepts Economic Incentives Offer From The City Of Gary, Indiana For $30 Million Towards 70 MeV Cyclotron Project
10. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
11. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... VIENNA , Sept. 17, 2014 ... compelling, quantitative data from a study of the cost ... at the 50 th Annual Meeting of the ... a poster session today, Christian Frois , Ph.D., ... in a series of planned Intarcia-sponsored, retrospective studies to ...
(Date:9/17/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, today ... trading in the United States ... commence on September 17, 2014 on the OTCQX under ... on the TSX Venture Exchange under its existing symbol ...
(Date:9/17/2014)... 17 de septiembre de 2014  Cryoport, ... proveedor mundial de soluciones logísticas avanzadas criogénicas ... la vida, anunció hoy la contratación de ... con sede en Rótterdam, Países Bajos, para ... Europa en rápido crecimiento. Según los términos ...
(Date:9/17/2014)... Scotland , September 17, 2014 /PRNewswire/ ... new mode of action from a truly ... decade  MGB Biopharma, a biopharmaceutical ... anti-infectives, announces today that it has secured ... its lead antibacterial, MGB-BP-3, against a range ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... , , , ... NGSX ), a biopharmaceutical company focused on developing and commercializing ... Goodwin to its Board of Directors as a director and Audit ... President and CEO of Keren Pharmaceutical, a company focused on exploiting ...
... , , , WALTHAM, ... leading research and advisory firms for pharmaceutical and healthcare issues, ... most notably Novartis,s Diovan -- the hypertension drug market will ... the market will decrease by 1.4 percent annually and thereafter ...
... , GAITHERSBURG, Md., Aug. 25 GenVec, Inc. (Nasdaq: ... Phase 2 Small Business Innovation and Research (SBIR) grant from the ... Institutes of Health (NIH) to support the development of GenVec,s vector ... http://www.newscom.com/cgi-bin/prnh/ 2 0081205/DC50112LOGO ) , , ...
Cached Biology Technology:NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents 2GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development 2
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical ... the circulating protein apolipoprotein E, called apoE3, helps repair ... called apoE4, do not get the benefit of this ... , "We believe that we have identified one mechanism ... why a genetic variant, apoE4, is detrimental," said ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
(Date:9/17/2014)... including MRSA and MSSA could be curbed by ... the scaly surface of shark skin, according to ... Antimicrobial Resistance and Infection Control . , The ... spread of human disease bacteria through touching, sneezes ... arrangement of ridges formulated to resemble shark skin. ...
Breaking Biology News(10 mins):Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3Sharks' skin has teeth in the fight against hospital superbugs 2
... real cost of Herceptin is borne by other patients whose ... doctors in this week’s BMJ. , New guidance from the ... (Herceptin) in early breast cancer, but it provides no extra ... to release this extra money. This leaves medical staff with ...
... larvae, warmed in a toasty lab chamber, are giving Cornell ... see how genes are expressed in living tissue. , Using ... Watt W. Webb, researchers have for the first time been ... activate their genes to synthesize key proteins in fruit fly ...
... protein converts chemical energy to mechanical force, thus powering ... structural model by University of North Carolina at Chapel ... a scientific mystery: how the protein dynein fuels itself ... include mitosis, or cell division into identical cells. ...
Cached Biology News:Other patients bear the real cost of Herceptin 2Researchers use multiphoton microscopy to watch chromosomes in action 2Researchers use multiphoton microscopy to watch chromosomes in action 3UNC scientists solve mystery of how largest cellular motor protein powers movement 2